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Zika virus (ZIKV) is a mosquito-transmitted flavivirus that caused a large outbreak in 
Latin America in 2015 with unique clinical manifestations not associated with other flavivirus 
infections. These manifestations included a spectrum of congenital defects such as 
microcephaly, fetal loss, and intra-uterine growth restriction. The factors that contribute to these 
adverse pregnancy outcomes are largely unknown, though there is some evidence to suggest 
that the immune response may play a role in mediating pregnancy pathology during viral 
infection. We hypothesized that interferon gamma (IFN-γ) regulates pregnancy pathology and 
viral replication during congenital ZIKV infection. To test this, we generated pregnancies using 
IFN-γ receptor knock-out mice on Ifnar1-/- background to generate pregnancies in which 
maternal, fetal, or both tissues were deficient of IFN-γ signaling. Lesser amounts of ZIKV RNA 
were detected in fetuses in which maternal IFN-γ signaling was intact than in fetuses lacking 
maternal IFN-γ signaling, suggesting an antiviral role for maternal IFN-γ signaling. Other groups 
have demonstrated that fetuses with intact IFNAR signaling have higher rates of resorption. 
Surprisingly, no pathology was observed in fetuses with intact fetal IFNAR signaling when IFN-γ 
signaling was ablated. We hypothesized that IFN-γ was acting downstream of IFNAR signaling 
to elicit the fetal IFNAR dependent pathology observed by other groups. To test this, we first 
tried to replicate the observed results by setting up a similar cross using Ifnar1+/- dams. We did 
not observe pathology in the resulting fetuses. We therefore conclude that all future experiments 
should be performed on an Ifnar1-/- background. 
Introduction  
Zika virus (ZIKV) is a flavivirus closely related to dengue virus, West Nile virus, and 
yellow fever virus. Prior to 2007, the first major ZIKV outbreak in Micronesia, ZIKV had rarely 
been connected to human disease cases1. Since then, it has been implicated as the cause of a 
2013 outbreak in French Polynesia and a 2015 outbreak in Latin America, among others1. ZIKV 
infection, especially during the first trimester, has been associated with adverse pregnancy 
3 
 
outcomes including fetal loss, intrauterine growth restriction (IUGR), and congenital birth defects 
including microcephaly1; these outcomes have not been associated with other flaviviruses2. 
Similar congenital abnormalities are associated with infection with other viruses during 
pregnancy, such as rubella virus and cytomegalovirus2.   
Interferons are a key component of the innate immune response against virus infection. 
There are three classes of interferon; the focus of this study is the type II interferon, also known 
as Interferon-γ (IFN- γ). Its receptor is comprised of two subunits, IFNGR1 and IFNGR2, which 
when bound by IFN-γ activate the JAK/STAT pathway, leading to STAT1 phosphorylation and 
the formation of STAT1 homodimers. These homodimers translocate to the nucleus where they 
bind to gamma activated sequences (GAS) to promote the transcription of surrounding genes 
whose protein products exhibit antiviral properties. This differs from the pathway of type I 
interferons, which signal through a different receptor, comprised of IFNAR1 and IFNAR2 
subunits. Activation of this receptor leads to the formation of STAT1-STAT2 heterodimers, 
which bind to other sequences (interferon stimulated response element, ISRE) that ultimately 
promote antiviral protein production. IFN-γ is a pro-inflammatory cytokine secreted by natural 
killer (NK) cells as well as TH1 and CD8+ T cells. 
IFN-γ signaling leads to further activation and recruitment of NK and T cells. It therefore serves 
as a link between the innate and adaptive immune system. During pregnancy, IFN-γ has  
additional roles, such as facilitating spiral artery remodeling and brain development3.  
The placenta is a fetal-derived tissue that serves as a barrier between the developing 
fetus and its mother and is the site of nutrient, gas, and antibody exchange. It is anchored to a 
maternal-derived tissue known as the decidua. The close proximity of the placenta and the 
decidua, two genetically distinct tissues, necessitates a unique immunological relationship in 
order to prevent rejection of the fetus. A majority of the leukocytes in the decidua are NK cells, 
although these decidual NK cells (dNK) exhibit low cytotoxicity as compared to peripheral NK 
cells circulating in the blood (pNK)4, though dNK cells can attain their full cytotoxic potential in 
4 
 
response to cytokines or receptor-ligand interactions5.NK cells are lymphocytes involved in the 
innate defense against viral infection. They are able to recognize and induce apoptosis in cells 
that are virally infected. NK cells secrete IFN-γ and are also activated by IFN-γ; it is possible 
that excessive IFN-γ secretion at the maternal-fetal interface as a result of viral infection could 
result in activation of decidual NK cells, disrupting the balance of the immune environment that 
allows for a healthy pregnancy.  
IFN-γ in the context of ZIKV congenital infection has not been studied, though other 
cytokines have been. It has been previously shown that type I interferon signaling restricts ZIKV 
replication in the placenta, though mouse fetuses with intact type I interferon signaling exhibit  
more pathology and higher rates of resorption6. Type III interferon signaling also plays a role in  
controlling ZIKV replication in the placenta in a gestational stage-dependent manner7. Though 
the role of IFN-γ in ZIKV congenital infection is not known, IFN-γ signaling has been has been 
implicated in mediating placental pathology, resorption, and miscarriage during infections with 
other congenital pathogens including Plasmodium falciparum8, Toxoplasma gondii9, and 
Brucella abortus10. We hypothesize that IFN-γ signaling from the maternal or fetal tissues 
regulates ZIKV replication in the placenta and instigates fetal pathology. To test this we set up 
various crosses using IFN-γ receptor knock-out mice to generate pregnancies in which 
maternal, fetal, or both tissues were deficient of IFN-γ signaling. We infected these pregnant 
dams with ZIKV to determine if IFN-γ is important for controlling ZIKV replication and inducing 
fetal pathology and whether this occurs through signaling in fetal or maternal tissues.  
Materials and Methods  
Matings  
All mouse experiments were performed under protocols approved by the UNC  
Institutional Animal Care and Use Committee.  All mice were on a C57BL/6 background and 
were originally obtained from Jackson Laboratories. All mice were bred and maintained at UNC. 
The days on which matings were set up were labelled as embryonic day 0 (E0). On E1, a tail 
5 
 
sample was taken from the sires for genotyping and the dams were weighed. Weight gain of 
≥1.5 grams between E1 and E7 was considered to indicate pregnancy. Dams with intact Ifnar1 
were treated on E6 or E8 with 1 or 2 mg of the Ifnar1 blocking monoclonal antibody MAR1-5A3 
by intraperitoneal injection. For E7 infections, all dams were infected with 1000 focus-forming 
units (FFUs) of ZIKV strain PRVABC59 or FSS13025 through a subcutaneous footpad injection. 
For E9 infections, pregnant dams were infected with either 103 or 105 FFUs of ZIKV strain 
PRVABC59 through a subcutaneous footpad injection. The maternal brain, spleen, and serum 
as well as the fetuses and associated placentas were harvested on E15.  
Viruses  
ZIKV strain PRVABC59, a human clinical isolate from the 2015 outbreak in Puerto Rico, 
provided by the US Centers for Disease Control and Prevention, Division of Vector-borne 
Diseases, and ZIKV strain FSS13025, a human clinical isolate from Cambodia in 2010, provided 
by the World Reference Center for Emerging Viruses and Arboviruses, were used for all 
infections. Stocks were maintained at -80°C after two passages on Vero cells.  
RNA Extraction  
Mouse tissues were homogenized for 60 seconds in 600 μL of PBS with silica beads 
using a Roche MagnaLyser and then centrifuged for 2 minutes at 8000 rpm. RNA was extracted 
from 150 μL of the homogenate using the Qiagen RNeasy mini kit according to the included 
protocol. The RNA was eluted in 30 μL RNAse-free water and stored at -80°C. 
qRT-PCR.  
qRT-PCR was performed using the BioRad iScrpt qRT-PCR kit along with custom 40x 
ZIKV primer probe set targeting the envelope protein (ZIKV-1: 
TTGGTCATGATACTGCTGATTGC, ZIKV-2: CCTTCCACAAAGTCCCTATTGC, ZIKV-3: /56-
FAM/CGGCATACA/ZEN/GCATCAGGTGCATAGGAG/3IABkFQ/). Standard curves were 




 Fetuses from crosses resulting in mixed litters were genotyped. The Quantabio 
Accustart II Mouse Genotyping Kit was used to extract DNA from fetal resorptions and to 
prepare PCR samples. For primers, the Jax IFNAR-/- primer set was used (Common Forward: 
CGAGGCGAAGTGGTTAAAAG, MT Reverse: AATTCGCCAATGACAAGACG, WT Reverse: 
ACGGATCAACCTCATTCCAC). The WT IFNAR PCR product is 155-base pairs in length.  
 Results 
Maternal IFN-γ signaling exhibits antiviral properties  
  We used fetal viral load to assess viral transmission across the placenta and replication 
in the developing fetus. Fetuses from Group A matings in which neither the mother nor the 
fetuses were competent for IFN- 𝛼/𝛽 and IFN-γ signaling had on average higher viral titers than 
both Group B and Group D (Fig. 1c). In Group B, fetal IFN- 𝛼/𝛽 signaling was restored, 
suggesting an antiviral role for fetal IFN-𝛼/𝛽 signaling. In Group D, both maternal and fetal IFN-γ 
signaling was restored. When compared to Group C, in which only fetal IFN-γ signaling was 
restored, Group B matings had greater amounts of ZIKV RNA on average, suggesting a role for 
maternal IFN-γ signaling in controlling ZIKV replication in the developing fetuses (Fig. 1c). 
Fetal IFNAR signaling does not elicit pathology in Ifngr1-/- fetuses in an Ifngr1-/- 
background 
To examine the potential roles for interferons in eliciting pregnancy pathology, we 
generated pregnancies in which Ifnar1, Ifngr1, or both were ablated in the dam and/or the 
resulting fetuses. The general experimental design is outlined in Fig. 1a and the genotypes and 
Groups are listed in Fig. 1b. We used fetal weight as an indicator of fetal pathology, where 
diseased fetuses are smaller. In Group A matings, neither the mother nor the fetus were 
competent for IFN- 𝛼/𝛽 and IFN-γ signaling (Fig. 1d). Fetuses from these crosses have healthy 
fetal weights, as do the fetuses resulting from Groups B, C, and D (Fig. 1d), therefore we could 
not draw conclusions about the individual roles of maternal and fetal IFN- 𝛼/𝛽 and IFN-γ 
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signaling in relation to the observed pathology. The viral loads in the spleens of the pregnant 
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Figure 1: Viral load and fetal weight data in IFN-γ experiments 
a) General experimental design b) Each of the four rows represents a mating designated by a 
letter; matings will be referenced from here on as “Group x”. Column two lists the genotype of 
the dam, column three lists the genotype of the sire, and column four lists the resulting genotype 
of the fetus and placenta. Bold red indicates competent IFNAR signaling while bold blue 
indicates competent IFNGR signaling. 
c) Viral load measured by qRT-PCR for each of the listed pregnancies, clustered according to 
the crosses listed in panel a. The dotted line represents the limit of detection. The mean is 
indicated by a bar. d)  Fetal weight data from each of the listed pregnancies, clustered 
according to the crosses listed in panel a. The mean is indicated by a bar.  e) Viral load 
measured by qRT-PCR on RNA extracted from the spleens of dams from each of the listed 
pregnancies, clustered according to the crosses listed in panel a. The dotted line represents the 




Fetal IFNAR signaling does not elicit consistent pregnancy pathology in Ifnar+/- dams  
To test whether the lack of pathology observed in fetuses from Group B in Figure 1 was 
due the absence of IFN-γ signaling or problems with the experimental design, we generated 
pregnancies between three Ifnar1+/- dams and Ifnar1-/- sires and labeled these pregnancies DF, 
DG, and DH. The experimental design is outline in Fig. 2a. The resulting fetuses of these 
pregnancies are shown in Fig. 2b. Half of the resulting fetuses from these crosses are 
competent for type I interferon signaling. Consistent fetal IFNAR-dependent pathology was not 
observed in these crosses, as demonstrated by a healthy average fetal weight in two of the 
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Figure 2: Viral load and fetal weight data in Ifnar1+/- x Ifnar1-/- mice experiments 
a) General experimental design. b) Fetuses in utero (left) and fetuses and their associated 
placentas after dissection (right) from three dams (DF, DG, and DH).  c) Viral load measured by 
qRT-PCR for each of the fetuses from the listed matings. The dotted line represents the limit of 
detection. The mean is indicated by a bar. d) Fetal weight data for the listed matings; 
resorptions are valued as 0 g. The mean is indicated by a bar. e) Viral load measured by qRT-
PCR for the maternal spleens. The dotted line represents the limit of detection. The mean is 
indicated by a bar. f) Genotyping of the fetuses from matings DF, DG, and DH. A single band at 
250 bp indicates an Ifnar1-/- fetus while a band at 250 bp and at 155 bp indicates a Ifnar1+/- 




WT mice are not a suitable model for congenital ZIKV infection 
 To optimize the experimental design for future pregnancies with clear, consistent 
phenotypes, we manipulated several experimental parameters in wildtype mice, as reflected in 
Figure 3a. Increasing the amount of MAR1-5A3 (Group II) and/or the amount of virus (Group III) 
did not result in a detectable difference in fetal viral load (Fig. 3b), fetal weight (Fig. 3c), or 
maternal viral load (Fig. 3d). Infecting at E7 as opposed to E9 and with FSS13025 as opposed 
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Figure 3: Viral load and fetal weight data in wildtype mice experiments 
a) Each of the five rows represents a mating designated by a Roman numeral; matings will be 
referenced from here on as “Group I,II,” etc. Columns 2-6 outline the experimental parameters 
for each of the groups. b) Viral load measured by qRT-PCR for each of the listed pregnancies, 
clustered according to the crosses listed in panel a. The dotted line represents the limit of 
detection. The mean is indicated by a bar. c) Fetal weight data from each of the listed 
pregnancies, clustered according to the crosses listed in panel a. The mean is indicated by a 
bar. d) Viral load measured by qRT-PCR on RNA extracted from the spleens of dams from each 
of the listed pregnancies, clustered according to the crosses listed in panel a. The dotted line 










I WTxWT E9 1 mg PRVABC59 1x103 FFUs 
II WTxWT E9 2 mg PRVABC59 1x103 FFUs 
III WTxWT E9 2 mg PRVABC59 1x105 FFUs 
IV WTxWT E7 2 mg PRVABC59 1x103 FFUs 




We initially hypothesized that maternal and/or fetal IFN-γ signaling regulates both viral 
replication in the fetus and pregnancy pathology. Viral loads in the fetuses from matings in 
which only fetal IFN-γ signaling (Group C) is present were similar to those in fetuses from  
matings in which neither the mother or the fetus had competent IFN- 𝛼/𝛽 nor IFN-γ  signaling  
(Group A), suggesting that fetal IFN-γ signaling does not have an effect on ZIKV replication (Fig. 
1c). This may be due to the fact that the IFN-γ receptor gene is not expressed in all fetal derived 
cells by midgestation, including the trophoblast giant cells, the outer layer of the mouse  
placenta11. However, upon the restoration of maternal IFN-γ signaling (Group D), we detected 
less virus in the resulting fetuses suggesting that maternal IFN-γ signaling reduces ZIKV 
replication or transplacental transmission. This same conclusion can be drawn for fetal IFN- 𝛼/𝛽 
signaling, as matings in which only the fetus is competent for IFN- 𝛼/𝛽 signaling (Group B) have 
fetuses with similar viral loads to those from Group D (Fig. 1c). Our data do not support our 
hypothesis that IFN-γ signaling impacts pregnancy pathology, as assessed through fetal weight, 
as fetuses from Group D and Group C had healthy weights (Fig. 1d).  
It was previously demonstrated that Ifnar1+/- fetuses born to Ifnar1-/- mothers infected  
intravaginally with 1.5x105 plaque-forming units (PFU) of  ZIKV strain FSS13025 (Cambodia  
2010) on E8.5 have fetal weights significantly lower than Ifnar1-/- fetuses from the same  
pregnancies6. Those results suggest that fetal IFN-𝛼/𝛽 signaling contributes to fetal pathology 
during congenital ZIKV infection. However, we did not see reduced fetal weights in the Group B  
matings in which Ifnar1+/-, Ifngr1-/- fetuses were born to Ifnar1-/-, Ifngr1-/- mothers. Although IFN-γ 
signaling was ablated in this cross, it was similar to the previously published study in that only 
the fetus was competent for type I interferon signaling. It is possible that the intravaginal and 
subcutaneous inoculations result in infections that present differently, as intravaginal inoculation 
may lead to a transvaginal ascending infection or hematogenous infection, while subcutaneous 
inoculations primarily result in hematogenous infections. Furthermore, we used a different ZIKV 
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strain, PRVABC59, another contemporary Asian lineage strain. It may be the case that there are 
strain specific differences that correspond to differential outcomes in congenital ZIKV infection. 
Though the Cambodian and Puerto Rican strains have 99.56% amino acid identity, FSS13025 
was found to induce a greater amount of IFN-γ , as well as other inflammatory cytokines, in the 
brain tissue of Stat2-/- mice12. Future experiments could aim to understand this possible strain 
specific difference in immune-mediated pregnancy pathology.  
 Alternatively, these results could suggest that IFN-γ is acting downstream of type I IFN 
signaling to mediate the pathology demonstrated when IFN-γ signaling is present. To test this 
hypothesis, we first tried to replicate the previously published results on fetal type I IFN signaling 
by setting up a similar cross. We mated Ifnar1+/- dams to Ifnar1-/- sires, generating pregnancies 
in which the litters contained both Ifnar1-/- and Ifnar1+/- fetuses. Interestingly, although all three 
dams had similar amounts of ZIKV RNA in their spleens (Fig. 2e), the fetuses from each of the 
pregnancies had different amounts of ZIKV RNA (Fig. 2c). Fetal viral load seemed to have a 
negative correlation to fetal weight, as pregnancy DF, which had the lowest average fetal weight 
(Fig. 2d), had the highest average fetal viral load (Fig. 2c), while pregnancy DH had the highest 
average fetal weight (Fig. 2d) and the lowest average fetal viral load (Fig. 2c). This could be 
related to the amount of fetuses in the pregnancy, or the amount of Ifnar-/- fetuses present.  
However, we did not see consistent IFNAR dependent pathology in the resulting fetuses from 
these pregnancies (Fig. 2b-f).  
 We altered several factors in our infection scheme in wild-type mice to optimize our 
experiments and find conditions in which pathology is consistent and reproducible. We used 
PRVABC59 for most infections as it has been found to cause pregnancy pathology in 
immunocompetent mice13 and fetal loss in nonhuman primates14. We did not see any significant 
differences in fetal weight, fetal head viral load, or maternal spleen viral load between wild-type 
mice treated with 1 or 2 mg of the IFNAR blocking antibody MAR1-5A3, between wild-type mice 
infected on E7 or E9, or between wild-type mice receiving 103 or 105 FFUs of ZIKV strain 
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PRVABC59 (Fig. 3b-d).  FSS13025 has been shown to cause pregnancy pathology in IFNAR-/- 
models of congenital infection6,15, therefore we also infected a set of pregnant WT mice on E7 
with 103 FFUs of FSS13025. There was no pathology evident (Fig. 3c). Combined with the data 
from the Ifnar+/- mice (Fig. 2), we concluded that future experiments should be performed on an 
Ifnar-/- background. 
Small animal models of infection allow us to obtain many samples over a relatively short 
time-span, but they are not without limitations. ZIKV targets human STAT2 for degradation, but 
it cannot antagonize mouse Stat216. The mouse model of ZIKV pathogenesis that we use 
therefore lacks the Ifnar1 portion of the IFN-𝛼/𝛽 receptor, allowing the virus to replicate to  
high titers17. All mice used in these experiments either lacked the IFN-𝛼/𝛽 receptor or were 
treated with an Ifnar1 blocking antibody in order to get a sufficient level of viremia in the mother. 
These two methods result in different levels of viral replication; MAR1-5A3 treated mice have 
lower viral loads than the receptor knock-outs. Nevertheless, tissues that may otherwise be 
protected by type I interferon signaling are susceptible in this model.  Additionally, the effects  
cross-talk between IFN- 𝛼/𝛽 and IFN-γ18 is not apparent under these conditions.  
 It is also important to note that both type I IFNs and IFN-γ are involved in  
facilitating uterine artery remodeling during pregnancy3; dams incapable of responding to these 
signals may have aspects of their pregnancies that are fundamentally different than their 
wildtype counterparts. Abnormal vasculature at the maternal-fetal interface could affect the 
fetus’s susceptibility to infection, or possibly be mistaken as pathology due to infection.  
The structure of the human and mouse placentas are similar in that they are both in 
direct contact with maternal blood, but the structures differ in that the mouse placenta has one  
additional layer of syncytiotrophoblast cells2. The arrangement of cell types also differs between 
the mouse and human placenta. Cytotrophoblasts in the mouse placenta are in direct contact 
with maternal blood, whereas in the human placenta, cytotrophoblasts are surrounded by the 
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syncytiotrophoblast layer and are not exposed to maternal blood.2 The mechanism used by 
ZIKV to cross the placenta in the mouse model may not represent what occurs in humans.   
Lastly, we used an inbred mouse line to control for the confounding effects of genetic 
variation. However, because the mice are genetically identical, this model poorly represents the 
normal semi-allogeneicity at the maternal-fetal interface, so may not capture pathology linked to 
immune rejection of non-self tissues. We are currently generating pregnancies between 
C57BL/6 and Balb/c mice to examine this effect. 
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